GlaxoSmithKline (GSK) today announced final results of a Phase II proof-of-concept clinical trial of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3 positive patients with stage IB or II Non-Small Cell Lung Cancer (NSCLC).
In the first scientific study of its kind, shark cartilage extract, AE-941 or neovastat, has shown no benefit as a therapeutic agent when combined with chemotherapy and radiation for patients with advanced non-small cell lung cancer, researchers say.
Researchers at the University of Alberta (Edmonton, AB) and Cortex Pharmaceuticals (Irvine, CA) believe that AMPAKINE drugs may provide protection from drug-induced respiratory depression, while simultaneously allowing the sedative or analgesic to continue working as it was intended.
ALIMTA? (pemetrexed for injection) showed additional utility in the treatment of the most diagnosed type of cancer , according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).
Enzastaurin, an investigational targeted, oral agent under development by Eli Lilly and Company, showed encouraging results in treating patients with late-stage non-small cell lung cancer (NSCLC), according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).
In the first scientific study of its kind, shark cartilage extract, AE-941 or Neovastat, has shown no benefit as a therapeutic agent when combined with chemotherapy and radiation for patients with advanced non-small cell lung cancer, according to researchers at the University of Texas M. D. Anderson Cancer Center.
Last year, a groundbreaking international project found that a group of Japanese patients with advanced non-small cell lung cancer survived longer ?and had a higher rate of side effects ? than U.S. patients with the same diagnosis,.when both groups were given two well-known drugs for the disease.
Researchers at Eli Lilly and Company are actively investigating the efficacy and safety of lung cancer treatments ALIMTA (pemetrexed for injection) and GEMZAR (gemcitabine HCl for injection) in treating non-small cell lung cancer in African-Americans, Hispanics and other diverse populations.
A new study reveals that first-degree relatives of patients with early-onset lung cancer are at an increased risk of developing other types of cancer.
New research shows that statins appear to protect against the development of lung cancer. The large population study, conducted by researchers from Louisiana State University and the Overton Brooks VA Medical Center, consisted of data collected over a 6-year period from the VA Health Care System.